About this Event
The Defense Advanced Research Projects Agency (DARPA), along with researchers at top universities and businesses across the country, have been running flat-out to develop game-changing therapeutics and diagnostics in response to the COVID-19 pandemic. The agency and its partners are leveraging DARPA’s prior developments on RNA and DNA vaccines as well as its Pandemic Preparedness Platform to advance truly innovative bio-technologies quickly to maximize their impact on society. DARPA research teams are seeking investment capital for promising companies to complement their research funding and significantly shorten the timeline from lab to patient-use while scaling to achieve a high level of public accessibility.
Eligibility Criteria of Participating Investors
This session is strictly open to accredited or qualified investors only (or ‘accredited’ investor equivalents by jurisdiction, i.e. professional/sophisticated investors), seeking new investment opportunities to co-invest. There is no obligation to invest in the investments presented.
ABOUT THE R3 COALITION
Launched in May 2020, the Response, Recovery, and Resilience Investment Coalition (R3 Coalition) aims to streamline impact investing efforts that will address the large-scale social and economic consequences of COVID-19. This initiative is a collaboration across prominent impact investing networks – to be managed by the Global Impact Investing Network as the organizing body – and is supported by a group of leading foundations. Learn more about the R3 Coalition: thegiin.org/r3coalition
For more information and to register, click here.
